

Abstract

The invention relates to the use of SLIM3 for binding to an androgen receptor or estrogen receptor β . The invention includes the use of a process for identifying ligands, which affect the interaction of SLIM3 and an androgen receptor or estrogen receptor β , so that the transcription, which is controlled by the receptor, is increased or decreased. Ligands, which are antagonists or agonists, are the preferred target of the identification.